Sibylla Biotech

About:

Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.

Website: https://www.sibyllabiotech.it/

Twitter/X: sibyllabiotech

Top Investors: CDP Venture Capital, Seroba Life Sciences, V-Bio Ventures, VI Partners, Vertis

Description:

Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.

Total Funding Amount:

23M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Trento, Trentino-Alto Adige, Italy

Founded Date:

2017-01-01

Contact Email:

contact(AT)sibyllabiotech.it

Founders:

Number of Employees:

11-50

Last Funding Date:

2022-10-04

IPO Status:

Private

Industries: